Pharmaceutical firm Genentech has received Food and Drug Administration approval for its thrombolytic agent Cathflo Activase. The product is a tissue plasminogen activator (t-PA) indicated for the restoration of function to central venous access devices (CVADs), as assessed by the ability to withdraw blood, according to the South San Francisco, CA-based vendor.
By AuntMinnie.com staff writersSeptember 6, 2001
Related Reading
t-PA highly effective in unclogging catheters, January 23, 2001
Copyright © 2001 AuntMinnie.com